Definitive proxy statements

Pay vs Performance Disclosure

v3.26.1
Pay vs Performance Disclosure - USD ($)
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Pay vs Performance Disclosure          
Pay vs Performance Disclosure, Table
Year-end value of $100
invested
on 12/31/2020 in:
Year
Summary
Compensation
Table Total for
CEO(1)
$
Compensation
Actually Paid to
CEO(2)
$
Average
Summary
Compensation
Table Total for
Non-CEO
NEOs(3)
$
Average
Compensation
Actually Paid to
Non-CEO
NEOs(2) (3)
$
RIGL(4)
$
NASDAQ
Biotechnology
Index(4)
$
Net Income
(Loss)
(in millions)
$
Total Revenue
(in millions)
$
2025 4,658,805  8,675,148  1,813,423  3,052,463  122.37  119.92  367.0  294.3 
2024 2,998,688  5,068,841  1,301,566  1,710,967  48.06  90.58  17.5  179.3 
2023 3,440,790  2,061,002  1,077,527  671,460  41.43  91.84  (25.1) 116.9 
2022 2,864,120  1,465,142  1,232,862  872,422  42.86  88.53  (58.6) 120.2 
2021 3,428,041  866,863  1,252,576  647,412  75.71  99.37  (17.9) 149.2 
       
Company Selected Measure Name Total Revenue        
Named Executive Officers, Footnote (1)Raul Rodriguez has been the CEO of the Company since November 2014 and has been its president since May 2010.
(3)Non-CEO NEOs reflect the average Summary Compensation Table total compensation and average Compensation Actually Paid for the following executives by year:
2025: Dean Schorno, Raymond Furey, David Santos and Lisa Rojkjaer
2024: Dean Schorno, Raymond Furey, David Santos and Lisa Rojkjaer
2023: Dean Schorno, Wolfgang Dummer (Dr. Dummer resigned from Rigel in March 2023), David Santos and Raymond Furey
2022: Dean Schorno, Dolly Vance (Ms. Vance retired from Rigel in October 2022), Wolfgang Dummer, David Santos, and Raymond Furey
2021: Dean Schorno, Dolly Vance, Wolfgang Dummer, and David Santos 		       
Peer Group Issuers, Footnote Total Shareholder Return (“TSR”) is determined based on the value of an initial fixed investment of $100 as of December 31, 2020, and the reinvestment of all dividends are assumed. The TSR peer group consists of the NASDAQ Biotechnology Index, the same peer group used in our Annual Report.        
PEO Total Compensation Amount $ 4,658,805 $ 2,998,688 $ 3,440,790 $ 2,864,120 $ 3,428,041
PEO Actually Paid Compensation Amount $ 8,675,148 5,068,841 2,061,002 1,465,142 866,863
Adjustment To PEO Compensation, Footnote
(2)Deductions from, and additions to, total compensation in the Summary Compensation Table by year to calculate Compensation Actually Paid include:
CEO
2025 2024 2023 2022 2021
($)
($)
($)
($)
($)
Total Compensation from Summary Compensation Table
 4,658,805  2,998,688  3,440,790  2,864,120  3,428,041 
Adjustments for Equity Awards
Adjustment for grant date values in the Summary Compensation Table (3,192,896) (1,683,160) (2,267,280) (1,771,120) (2,448,705)
Year-end fair value of unvested awards granted in the current year 3,335,754  1,788,710  1,217,867  795,491  578,006 
Year-over-year difference of year-end fair values for unvested awards granted in prior years 2,121,217  554,321  (427,053) (184,265) (950,857)
Fair values at vest date for awards granted and vested in current year 1,331,815  551,249  114,948  260,343  269,958 
Difference in fair values between prior year-end fair values and vest date fair values for awards granted in prior years 420,453  859,033  (18,270) (499,427) (9,580)
Forfeitures during the current year equal to prior year-end fair value -  -  -  -  - 
Total Adjustments for Equity Awards 4,016,343  2,070,153  (1,379,788) (1,398,978) (2,561,178)
Compensation Actually Paid (as calculated) 8,675,148  5,068,841  2,061,002  1,465,142  866,863 
       
Non-PEO NEO Average Total Compensation Amount $ 1,813,423 1,301,566 1,077,527 1,232,862 1,252,576
Non-PEO NEO Average Compensation Actually Paid Amount $ 3,052,463 1,710,967 671,460 872,422 647,412
Adjustment to Non-PEO NEO Compensation Footnote (2)Deductions from, and additions to, total compensation in the Summary Compensation Table by year to calculate Compensation Actually Paid include:
Average Non-CEO NEOs
2025 2024 2023 2022 2021
($)
($)
($)
($)
($)
Total Compensation from Summary Compensation Table 1,813,423  1,301,566  1,077,527  1,232,862  1,252,576 
Adjustments for Equity Awards
Adjustment for grant date values in the Summary Compensation Table (966,279) (537,416) (384,280) (541,865) (583,025)
Year-end fair value of unvested awards granted in the current year 1,199,979  563,100  144,805  248,969  137,627 
Year-over-year difference of year-end fair values for unvested awards granted in prior years 573,870  107,735  (144,445) (35,496) (221,116)
Fair values at vest date for awards granted and vested in current year 310,626  163,278  13,649  44,372  64,268 
Difference in fair values between prior year-end fair values and vest date fair values for awards granted in prior years 120,844  112,704  (9,756) (76,420) (2,918)
Forfeitures during the current year equal to prior year-end fair value -  -  (26,040) -  - 
Total Adjustments for Equity Awards 1,239,040  409,401  (406,067) (360,440) (605,164)
Compensation Actually Paid (as calculated) 3,052,463  1,710,967  671,460  872,422  647,412 
       
Compensation Actually Paid vs. Total Shareholder Return
CAP and Cumulative TSR / Cumulative TSR of the Peer Group
4870
        
Compensation Actually Paid vs. Net Income
CAP and Company Net Income (Loss)
4906
        
Compensation Actually Paid vs. Company Selected Measure
CAP and Total Revenue
4930
        
Total Shareholder Return Vs Peer Group
CAP and Cumulative TSR / Cumulative TSR of the Peer Group
4870
        
Tabular List, Table
Tabular List of Performance Measures
As noted in the CD&A, for 2025, the principal incentive elements in the Company’s executive compensation program were delivered in the form of annual incentives and equity awards. As is the case with many companies in the biotechnology industry, the Company’s annual incentive objectives are generally tied to the Company’s strategic and operational goals rather than financial goals. The following is a list of performance measures, which in the Company’s assessment represents the most important performance measures used by the Company to link compensation actually paid to the NEOs for 2025:
•U.S. Net Product Sales (2025 Cash Plan and 2026 Performance-Based Options
•Expansion of clinical pipeline (clinical trials, corporate development via acquisition and/or licensing) (2025 Cash Plan)
•Operating Expenses
•Adjusted EBITDA (2025 Cash Plan)
•Total Revenues*
*While not a direct component of the Company’s executive compensation program, revenue is included due to its reflection of the growth of our product sales. To measure growth in our product sales, a performance metric used under our annual incentive compensation program, we have identified revenue as our Company-Selected Measure which we believe reflects how well we have executed against our objective with respect to growth in our product sales. 		       
Total Shareholder Return Amount $ 122.37 48.06 41.43 42.86 75.71
Peer Group Total Shareholder Return Amount 119.92 90.58 91.84 88.53 99.37
Net Income (Loss) $ 367,000,000.0 $ 17,500,000 $ (25,100,000) $ (58,600,000) $ (17,900,000)
Company Selected Measure Amount 294,300,000 179,300,000 116,900,000 120,200,000 149,200,000
PEO Name Raul Rodriguez Raul Rodriguez Raul Rodriguez Raul Rodriguez Raul Rodriguez
Measure:: 1          
Pay vs Performance Disclosure          
Name U.S. Net Product Sales        
Measure:: 3          
Pay vs Performance Disclosure          
Name Expansion of clinical pipeline        
Measure:: 4          
Pay vs Performance Disclosure          
Name Operating Expenses        
Measure:: 5          
Pay vs Performance Disclosure          
Name Adjusted EBITDA        
Measure:: 6          
Pay vs Performance Disclosure          
Name Total Revenues        
PEO | Equity Awards Adjustments          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount $ 4,016,343 $ 2,070,153 $ (1,379,788) $ (1,398,978) $ (2,561,178)
PEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (3,192,896) (1,683,160) (2,267,280) (1,771,120) (2,448,705)
PEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 3,335,754 1,788,710 1,217,867 795,491 578,006
PEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 2,121,217 554,321 (427,053) (184,265) (950,857)
PEO | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 1,331,815 551,249 114,948 260,343 269,958
PEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 420,453 859,033 (18,270) (499,427) (9,580)
PEO | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 0 0 0 0 0
Non-PEO NEO | Equity Awards Adjustments          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 1,239,040 409,401 (406,067) (360,440) (605,164)
Non-PEO NEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (966,279) (537,416) (384,280) (541,865) (583,025)
Non-PEO NEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 1,199,979 563,100 144,805 248,969 137,627
Non-PEO NEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 573,870 107,735 (144,445) (35,496) (221,116)
Non-PEO NEO | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 310,626 163,278 13,649 44,372 64,268
Non-PEO NEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 120,844 112,704 (9,756) (76,420) (2,918)
Non-PEO NEO | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount $ 0 $ 0 $ (26,040) $ 0 $ 0